SPY767.36+1.72%QQQ693.02+1.13%BTC/USD80,200.05+3.70%DIA532.48+2.98%GLD372.10+3.57%TLT81.65+0.67%

Premium Services

Champions Oncology Inc

CSBRNASDAQ

Trade with Public

Trade with Public

$4.84

0.010.21%

Last update: Nov 4, 10:58 AM

Overview News Earnings Forecast EventsPrice TargetsFinancials Sentiment Ownership Compare Options Stock Report

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell

© 2026 Benzinga | All Rights Reserved

Champions Oncology (CSBR) Stock Price Target 2026

The average analyst price target for Champions Oncology is $12, 147.9% above the current price. The one analyst covering it rates it Buy. The latest change came on Mar 12, 2025, when Craig-Hallum raised its price target on Champions Oncology from $8 to $12 and kept a Buy rating.

The Average Analyst Price Target for Champions Oncology is $12.

Price Target Range — 3 Quarters

Analyst Consensus — 1 Analysts

1Buy

Consensus RatingBuy# Analysts1Avg. Consensus PT$12Upside to Avg. PT+147.9%

Rating Trend — Last 9 Months

Latest Upgrades and Downgrades for Champions Oncology Stock

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Mar 12, 2025	Craig-Hallum	Matt Hewitt	PT Raise	Buy	$8→$12
Dec 12, 2024	Craig-Hallum	Matt Hewitt	PT Raise	Buy	$6→$8
Sep 12, 2024	Craig-Hallum	Matt Hewitt	Upgrade	Hold→Buy	$6
Mar 13, 2024	Craig-Hallum	Matt Hewitt	Downgrade	Buy→Hold	—

Analyst Ratings News

PRO
Craig-Hallum Maintains Buy on Champions Oncology, Raises Price Target to $12

Craig-Hallum analyst Matt Hewitt maintains Champions Oncology (NASDAQ:CSBR) with a Buy and raises the price target from $8 to $12.

Benzinga Newsdesk

PRO
Craig-Hallum Maintains Buy on Champions Oncology, Raises Price Target to $8

Craig-Hallum analyst Matt Hewitt maintains Champions Oncology (NASDAQ:CSBR) with a Buy and raises the price target from $6 to $8.

Benzinga Newsdesk

PRO
Craig-Hallum Upgrades Champions Oncology to Buy, Maintains Price Target to $6

Craig-Hallum analyst Matt Hewitt upgrades Champions Oncology (NASDAQ:CSBR) from Hold to Buy and maintains the price target from $6 to $6.

Benzinga Newsdesk

PRO
Craig-Hallum Downgrades Champions Oncology to Hold

Craig-Hallum analyst Matt Hewitt downgrades Champions Oncology (NASDAQ:CSBR) from Buy to Hold.

Benzinga Newsdesk

PRO
Roth MKM Maintains Buy on Champions Oncology, Lowers Price Target to $7.5

Roth MKM analyst Scott Henry maintains Champions Oncology (NASDAQ:CSBR) with a Buy and lowers the price target from $9 to $7.5.

Benzinga Newsdesk

PRO
Roth Capital Maintains Buy on Champions Oncology, Raises Price Target to $16

Roth Capital maintains Champions Oncology (NASDAQ:CSBR) with a Buy and raises the price target from $13.5 to $16.

Benzinga Newsdesk